Autres langues Tempus AI, Inc.

Actions

TEM

US88023B1035

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 29/09/2026			Varia. 5j.	Varia. 1 janv.
82,58 ^USD	-2,94 %		+6,98 %	+39,85 %

28/09	Tempus AI, Inc. obtient l’autorisation de la FDA pour Tempus ECG-MR, son produit d’intelligence artificielle conçu pour identifier les cas non diagnostiqués d’insuffisance mitrale	CI
28/09	Tempus AI obtient l’autorisation de la FDA pour son outil ECG-MR destiné à identifier les régurgitations mitrales modérées ou sévères	MT

Autres langues

28/09	Tempus AI, Inc. Receives FDA Clearance For Tempus ECG-MR AI Product Designed To Identify Undiagnosed Mitral Regurgitation
28/09	Tempus AI Receives FDA Clearance for ECG-MR Tool to Identify Moderate or Severe Mitral Regurgitation
28/09	Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
21/09	Tempus AI, Recursion Extend Data License, Amend Fee Structure
21/09	Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model
17/09	Health Care Up on Drug Development Hopes -- Health Care Roundup
14/09	AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033
11/09	Tempus AI, Inc. Launches Effort To Build The Largest Multimodal Whole-Genome Dataset To Advance AI-Driven Healthcare Innovation
11/09	Tempus AI Building Multimodal Whole-Genome Dataset for AI Research
11/09	Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation
09/09	Tempus AI Secures Up To $9.5 Million in US Agency Funding for Cardiology Agent
09/09	Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology
09/09	Q1 Report - Focused Execution Driving Growth
04/09	Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
03/09	Median Technologies Announces Formation of Strategic Review Committee and R&D Committee to Unlock Intrinsic Value and Accelerate Its eyonis Pan-Cancer Strategy
01/09	Afternoon Meeting: La renta fija empaña el inicio de septiembre
01/09	Bonds spoil September's opening
01/09	Analyst recommendations: Duolingo, Robinhood, Adobe, CrowdStrike, Salesforce…
24/08	Tempus AI Receives FDA Clearance For Tempus ECG-PH AI Product Intended To Detect Signs Of Pulmonary Hypertension From Standard ECGs
24/08	Tempus AI Gets FDA Clearance for AI-Enabled Pulmonary Hypertension Detector
24/08	Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs
21/08	Tempus AI Insider Sold Shares Worth $2,038,723, According to a Recent SEC Filing
21/08	Tempus AI Insider Sold Shares Worth $6,577,840, According to a Recent SEC Filing
21/08	Tempus AI Insider Sold Shares Worth $2,696,444, According to a Recent SEC Filing
21/08	Tempus AI Insider Sold Shares Worth $1,542,674, According to a Recent SEC Filing